|
|
Science Sparks @ ACTREC
|
7th November 2022 |
Vol. No. 11; Issue No. 551 |
|
Publications
|
1. Krishnamurthy MN, Pradosh A, Varghese D, Halder S (2022). Clinical pharmacologist from the eyes of a clinical pharmacologist: A questionnaire‑based survey. European Journal of Clinical Pharmacology.
2. Tiwari M, Rauthan A, Chavan P, Subramanian PG, Gujral S, Bhat V (2022). Quality evaluation of sample collection facilities of resource‑limited medical laboratories in various states of India: A comparison between accredited and nonaccredited laboratories. QAI Journal for Healthcare Quality and Patient Safety. 3:8-12
3. Gokarn A, Shenoy R, Punatar S, Mirgh S, Chichra A, Nayak L, Bonda A, Jindal N, Saroha M, Toshniwal A, Prayag P, Tripathi R, Kumar S, Bhat V, Biswas S, Khattry N (2022). Efficacy of artesunate for treatment of cytomegalovirus reactivation post allogeneic haematopoietic stem cell transplants. Bone Marrow Transplantation.
4. Kulkarni R, Gupta S (2022). Gynaecological oncology in India: Past, present and future. Indian Journal of Surgical Oncology.
5. Chopra S, Mulani J, Mittal P, Singh M, Shinde A, Gurram L, Scaria L, Dheera A, Kolhe S, Rane P, Ghadi Y, Rath S, Ghosh J, Gulia S, Gupta S, Kinhikar R, Laskar S, Agarwal J (2022). Early outcomes of abbreviated multi-fractionated brachytherapy schedule for cervix cancer during COVID-19 pandemic. Brachytherapy.
6. Dhumal S, Patil V, Noronha V, Prabahsh K (2022). Immune checkpoint inhibitors: Promising but still inaccessible treatment option for patients with head-and neck cancer in India. Cancer Research, Statistics, and Treatment. 5(3): 587-588.
7. Patil V, Muthuluri H, Choudhary J, Parekh D, Abraham G, Noronha V, Menon N, Dhumal S, Prabhash K (2022). Nivolumab in platinum-refractory head-and-neck cancers: A retrospective observational audit from a tertiary
cancer center. Cancer Research, Statistics, and Treatment. 5:468-73.
8. Kumar S, Shriyan B, Patil A, Yadav S, Jadhav S, Asar M, Krishnamurthy MN, Patil V, Joshi A, Noronha V, Prabhash K, Gota V (2022). Effect of ADME gene polymorphisms on pemetrexed pharmacokinetics in patients with non-small-cell lung cancer: A prospective study. Cancer Research, Statistics, and Treatment. 5: 437-44.
9. Sengar M, Jain H, Shet T, Sridhar E, Gota V, Rangarajan V, Laskar SS, Alahari A, Thorat J, Agarwal A, Sharma N, Gupta H, Kannan S, Kumar S, Nayak L, Menon H, Gujral S, Bagal B (2022). Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. British Journal of Haematology.
10. Lall S, Bhat V, Biswas S, Joshi A, Janu A (2022). Delftia acidovorans: An unusual pathogen from an adenocarcinoma lung patient with pleural effusion. Journal of Global Infectious Diseases.
|
|
|
|
Legends of Science
|
|
Bhalchandra Bhavanishankar Mundkur
Bhalchandra Bhavanishankar Mundkur obtained his Ph.D. from the Iowa state college of agriculture, USA, in 1930. His research interest was mycology and plant pathology. He established four genera, over a hundred new species, and new combinations of fungi. The smut genus Mundkurella was named in his honor. He served as Director of the Plant Protection Ministry of Food and Agriculture. A Fellow of the Indian National Science Academy, Dr. Mundkur was a member of the American Phytopathological Society and Founder President of the Indian Phytopathological Society.
|
|
|
|
Harendra Nath Ray
Harendra Nath Ray, an eminent parasitologist, received his Ph.D. from the University of London, UK, in 1930. He discovered many new genera and species in Rhizopoda, Mastigophora, Ciliophora, Gregaria, Coccidia, and Haemosphoridia. He was a pioneer in establishing the method of transmission of Thalesemma Annulate in cattle through the eggs of infected ticks. His notable discovery was the presence of small cysts clusters in the liver of the Himalayan flying squirrels depicting the exoerythrocytic schizogony of a malarial parasite referred to as a new genus Rayella. Dr. Ray was President of the Zoology and Entomology Section, Indian Science Congress; and Sectional President Third International Congress of Protozoology, Leningrad. He was also elected Fellow of the Royal School of Tropical Medicine and Hygiene, American Society of Parasitologists, and Zoological Society of India.
|
|
|
|
|
Do You Know?
The first licenced monoclonal antibody was Orthoclone OKT3 (muromonab-CD3) which was approved in 1986 for use in preventing kidney transplant rejection.
|
|
|
Cancer News
|
DNA 'nanotransporters' to treat cancer
|
02 November 2022, EurekAlert
|
Using the new drug transporter developed for doxorubicin, the team demonstrated that a specific drug-transporter formulation allows doxorubicin to be maintained in the blood and drastically reduces its diffusion towards key organs such as the heart, lungs and pancreas...
|
|
|
|
|
|
|
|
|
� 2022 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|